Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 22.0% in August

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,550,000 shares, an increase of 22.0% from the August 15th total of 1,270,000 shares. Currently, 7.8% of the shares of the company are short sold. Based on an average trading volume of 81,500 shares, the short-interest ratio is currently 19.0 days.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth $33,434,000. Vanguard Group Inc. acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth $14,104,000. Perceptive Advisors LLC acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth $17,215,000. Samsara BioCapital LLC acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth $4,611,000. Finally, Logos Global Management LP acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth $844,000. Institutional investors and hedge funds own 28.54% of the company’s stock.

NASDAQ DAWN opened at $20.55 on Tuesday. Day One Biopharmaceuticals has a 1-year low of $17.19 and a 1-year high of $28.70. The company has a 50 day simple moving average of $24.43.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, August 9th. The company reported ($5.04) EPS for the quarter, missing the consensus estimate of ($0.32) by ($4.72). Analysts predict that Day One Biopharmaceuticals will post 0.94 EPS for the current year.

A number of equities research analysts have recently weighed in on the stock. Cowen assumed coverage on shares of Day One Biopharmaceuticals in a research report on Monday, June 21st. They issued an “outperform” rating for the company. Piper Sandler assumed coverage on shares of Day One Biopharmaceuticals in a research report on Monday, June 21st. They issued an “overweight” rating and a $44.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of Day One Biopharmaceuticals in a research report on Monday, June 21st. They issued an “overweight” rating and a $38.00 price target for the company. Finally, Wedbush assumed coverage on shares of Day One Biopharmaceuticals in a research report on Monday, June 21st. They issued an “outperform” rating and a $30.00 price target for the company.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Further Reading: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.